Skip to main content
Autobound logo
Biogen10-K: Capex increase

Biogen acquires Alcyone Therapeutics for $85M+ to take over manufacturing and commercialization.

Read at SEC EDGAR

What happened

The acquisition of Alcyone Therapeutics for an initial $85M requires Biogen to integrate and manage end-to-end development, manufacturing, and commercialization for the ThecaFlex DRx device.

Source

SEC EDGARFeb 6, 2026

Annual report (Form 10-K)

Biogen 10-K for FY2025

Filing excerpt

In November 2025 we completed the acquisition of all of the issued and outstanding shares of Alcyone Therapeutics, Inc...

sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htmRead the full source

Other signals in this filing (11)

Extracted by Autobound

From the Signal API record
Signal
10-K: Capex increase

What this signalsFilings often name leadership changes, deals and spending plans.

Period
FY2025
Fiscal year end
12/31
Filed
Feb 6, 2026

More from Biogen

Company page →

More 10-K signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$85M (Initial consideration for Alcyone Therapeutics acquisition, with up to $75M in additional milestones.)

Details

CIK
875045
Accession number
0000875045-26-000013
Timeframe
Current year
Filing year
2026
Why it matters
Budget available
Signal category
Financial

Topics and mentions

Technologies

  • ASOs

Extraction

Confidence
High
Relevance
80%
Sentiment
Positive
Detected
Feb 10, 2026
signal_type
sec-10k
signal_subtype
capexIncrease

Use this data

Get every 10-K signal for Biogen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Biogen this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/cf3f89b8-8bc7-413a-afc5-dc62528d6362 returns this record as JSON. POST /v1/companies/enrich returns every signal for biogen.com.

{
  "signal_id": "cf3f89b8-8bc7-413a-afc5-dc62528d6362",
  "signal_type": "sec-10k",
  "signal_subtype": "capexIncrease",
  "detected_at": "2026-02-10T07:50:47.777+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "detail": "The acquisition of Alcyone Therapeutics for an initial $85M requires Biogen to integrate and manage end-to-end development, manufacturing, and commercialization for the ThecaFlex DRx device. This creates immediate needs for vendors specializing in post-merger integration, supply chain management, and commercial operations systems.",
    "metrics": {
      "timeframe": "current_year",
      "dollar_context": "Initial consideration for Alcyone Therapeutics acquisition, with up to $75M in additional milestones.",
      "dollar_millions": 85
    },
    "summary": "Biogen acquires Alcyone Therapeutics for $85M+ to take over manufacturing and commercialization.",
    "excerpts": "In November 2025 we completed the acquisition of all of the issued and outstanding shares of Alcyone Therapeutics, Inc...",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm",
    "filing_date": "2026-02-06",
    "filing_year": 2026,
    "fiscal_year_end": "12/31",
    "sales_relevance": "Budget available",
    "signal_category": "financial",
    "technologies_mentioned": [
      "ASOs"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.